Biotechnology ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr Emmanuelle Charpentier, announced today that the European Patent Office (EPO) has rejected arguments filed in opposition to European patent No EP2800811 jointly held by Dr Charpentier, the Regents of the University of California, and the University of Vienna, and affirmed the patentability of the inventions described. 10 February 2020